NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
09 Luglio 2024 - 1:00PM
Business Wire
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology
testing services company, today announced that it will report its
second quarter 2024 financial results after the close of the U.S.
financial markets on Monday, July 29, 2024. Company management will
host a webcast and conference call at 4:30 p.m. ET to discuss
financial results and recent highlights.
The live webcast may be accessed by visiting the Investor
Relations section of our website at ir.neogenomics.com. The webcast
will be archived and available for replay shortly after the
conclusion of the call.
To access the live call via telephone, dial (888) 506-0062
(domestic) or (973) 528-0011 (international) at least five minutes
prior to the call. The participant access code is 276062.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus in the world for physicians to help
them diagnose and treat cancer. The Company's Pharma Services
Division serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709121031/en/
Investor Contact Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact Andrea Sampson
asampson@sampsonprgroup.com
Grafico Azioni NeoGenomics (NASDAQ:NEO)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni NeoGenomics (NASDAQ:NEO)
Storico
Da Nov 2023 a Nov 2024